In a significant move aimed at enhancing diabetes care in India, USV Pvt Ltd has collaborated with Biogenomics to unveil INSUQUICK®, the nation’s inaugural biosimilar Insulin Aspart. The new insulin variant is poised to augment treatment accessibility for individuals grappling with diabetes.
India is grappling with a burgeoning diabetes epidemic, with approximately 11.4% of the adult population, translating to 101 million people, living with the condition. An additional 136 million individuals are categorized as pre-diabetic, facing an elevated risk of transitioning to full-fledged diabetes in a short span.
Key Features of INSUQUICK:
- Developed and manufactured entirely in India with 100% indigenous technology.
- Underwent a rigorous clinical program to adhere to global quality standards.
- Widely available in all metropolitan areas, as well as Tier I/II cities.
Prashant Tewari, Managing Director of USV Pvt Ltd, expressed the company’s commitment to enhancing the quality of life for those with diabetes. The strategic entry into injectables is poised to fortify the company’s market presence, especially in the diabetes segment. The collaboration with Biogenomics aims to provide global-quality insulin aspart to the diabetes community.
Dr. Sanjay Sonar, Co-Founder and President of Biogenomics, highlighted the significant research and development efforts spanning over a decade that resulted in the creation of insulin aspart, the first biosimilar in the rapid-acting insulin category.
Dr. Archana Krishnan, Co-Founder and Director of Biogenomics, emphasized that INSUQUICK is crafted entirely in India, utilizing indigenous technology with a structure conformation akin to a fingerprint. The insulin variant is available in cartridges, vials, and prefilled disposable pens, ensuring flexibility tailored to the unique needs of individuals with diabetes.
The introduction of INSUQUICK marks USV’s foray into the insulin market, with plans for continued expansion in the coming years through robust research and development endeavors. USV Pvt Ltd, with over six decades of legacy, holds a leadership position in diabetes and cardiac therapeutic segments in India.
BioGenomics, a science-driven biotechnology company, specializes in the development of biopharmaceuticals and biologics. The company’s vision revolves around ensuring continued access to life-saving biopharmaceuticals through adaptive innovation.